---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Cytotoxic chemotherapy"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Cytotoxic chemotherapy. Topics: Guideline summary of chemotherapy in metastatic uveal melanoma, Pooled response to systemic treatment across 40 studies of 841 evaluable participants, Temozolomide or dacarbazine as the control arm of a randomized phase 2 trial of selumetinib, Temozolomide or dacarbazine versus cabozantinib: randomized phase 2 Alliance A091201 trial, and 6 further topics. 10 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/cytotoxic-chemotherapy"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Cytotoxic chemotherapy

<a id="heading-2.2.2.1.4"></a>

## 2.2.2.1.4 Cytotoxic Chemotherapy

<a id="topic-2.2.2.1.4-1"></a>

### Guideline summary of chemotherapy in metastatic uveal melanoma

> “Response rates are low (<10%) regardless of the cytotoxic agent tested and whether it was used as monotherapy or in combination.”
> “Drugs evaluated in this setting include dacarbazine, temozolomide, treosulfan, cisplatin and fotemustine”
> “with no demonstrated OS benefit over best supportive care.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.4-2"></a>

### Pooled response to systemic treatment across 40 studies of 841 evaluable participants

> “Complete or partial remissions were observed in 39/841 patients (overall response rate [ORR] 4.6%; 95% confidence intervals [CI] 3.3–6.3%), no responses were observed in 22/40 studies.”
> “MUM is frequently treated with chemotherapeutics like dacarbazine, fotemustine, or gemcitabine/treosulfan although evidence for these regimens is limited.”

Source: [Buder et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3892799/)

<a id="topic-2.2.2.1.4-3"></a>

### Temozolomide or dacarbazine as the control arm of a randomized phase 2 trial of selumetinib

> “Randomized open-label phase II clinical trial comparing selumetinib versus chemotherapy.”
> “101 patients were randomized on a 1:1 ratio to selumetinib 75 mg orally twice daily on a continual basis (n=50) or chemotherapy (temozolomide 150 mg/m2 orally daily for 5 of every 28 days or DTIC 1000 mg/m2 intravenously every 21 days; investigator choice; n=51) until disease progression, death, intolerable toxicity, or withdrawal of consent.”
> “Median progression-free survival for those randomized to chemotherapy and selumetinib was 7 (95% CI, 4.3 – 8.4; median treatment duration of 8 weeks (IQR, 4.3–16)) and 15.9 weeks (95% CI, 8.4 – 21.1; median treatment duration of 16.1 weeks (IQR, 8.1–25.3)), respectively (hazard ratio 0.46; 95% CI, 0.30 – 0.71; p < 0.001).”
> “Median overall survival was 9.1 (95% CI, 6.1 – 11.1) and 11.8 months (95% CI, 9.8 – 15.7) for those randomized to chemotherapy and selumetinib, respectively (hazard ratio 0.66; 95% CI, 0.41–1.06; p=0.09).”
> “No objective responses were observed with chemotherapy.”

Source: [Carvajal et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4249701/)

<a id="topic-2.2.2.1.4-4"></a>

### Temozolomide or dacarbazine versus cabozantinib: randomized phase 2 Alliance A091201 trial

> “Alliance for Clinical Trials in Oncology A091201, a randomized phase II trial of the multiple TKI cabozantinib that also inhibits MET and VEGFR2 compared with temozolomide (TMZ) or dacarbazine (DTIC) in patients with metastatic UM.”
> “Patients with metastatic UM and RECIST measurable disease were randomized 2:1 to receive either cabozantinib (arm 1) versus temozolomide or dacarbazine (arm 2) with restaging imaging every two cycles.”
> “Rates of PFS4 in arm 1 and arm 2 were 32.3% and 26.7% (p=0.35), respectively, with median PFS time of 60 and 59 days (p=0.964; HR=0.99).”
> “Median overall survival was 6.4 months and 7.3 months (p=0.580; HR=1.21), respectively.”
> “Grade 3–4 CTCAE adverse events were present in 61.3%, 46.7%, and 37.5% in arms 1, 2 and 2X, respectively.”
> “MET/VEGFR blockade with cabozantinib demonstrated no improvement in PFS but an increase in toxicity relative to temozolomide/dacarbazine in metastatic UM.”

Source: [Luke et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7055933/)

<a id="topic-2.2.2.1.4-5"></a>

### Objective response with placebo plus dacarbazine compared with selumetinib plus dacarbazine

> “The objective response rate was 3% with selumetinib plus dacarbazine and 0% with placebo plus dacarbazine (two-sided P = .36).”

Source: [Carvajal et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29528792/)

<a id="topic-2.2.2.1.4-6"></a>

### Intravenous versus hepatic intra-arterial fotemustine: randomized phase 3 EORTC 18021 trial

> “The prospective randomized phase III trial (EORTC 18021) thus aimed to compare the efficacy and safety of HIA versus IV fotemustine in UM patients with metastases in liver only.”
> “Accrual was stopped after randomization of 171 patients based on the results of a futility OS analysis.”
> “HIA did not improve OS (median 14.6 months) when compared with the IV arm (median 13.8 months), hazard ratio (HR) 1.09; 95% confidence interval (CI) 0.79–1.50, log-rank P = 0.59.”
> “However, there was a significant benefit on PFS for HIA compared with IV with a median of 4.5 versus 3.5 months, respectively (HR 0.62; 95% CI 0.45–0.84, log-rank P = 0.002).”
> “An improved RR was seen in the HIA (10.5%) compared with IV treatment (2.4%).”
> “The main grade ≥3 toxicity related to HIA was catheter complications (12%) and liver toxicity (4.5%) apart from two toxic deaths.”

Source: [Leyvraz et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4433517/)

<a id="topic-2.2.2.1.4-7"></a>

### Temozolomide: phase 2 trial of 14 participants with liver metastases

> “we conducted a phase II clinical trial of temozolomide in patients with uveal melanoma metastatic to the liver.”
> “Fourteen patients were enrolled in the trial.”
> “No complete or partial responses were observed.”
> “We conclude that, like DTIC, temozolomide at the dose and schedule studied in this trial is not effective for the control of metastatic melanoma of uveal origin.”

Source: [Bedikian et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12777987/)

<a id="topic-2.2.2.1.4-8"></a>

### Temozolomide plus bevacizumab: noncomparative phase 2 study of 36 participants

> “This noncomparative phase II study evaluated a combination of bevacizumab (10 mg/kg on days 8 and 22) with temozolomide (150 mg/m 2 on days 1–7 and 15–21) in 36 patients with metastatic uveal melanoma (MUM).”
> “Median PFS and OS were 12 weeks and 10 months, respectively.”
> “In patients with MUM, a combination of bevacizumab plus temozolomide achieved a 6-month PFR of 23%.”

Source: [Piperno-Neumann et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4786360/)

<a id="topic-2.2.2.1.4-9"></a>

### Cisplatin, dacarbazine, and vinblastine as first-line treatment for unresectable metastases: phase 2 study

> “In the present phase II study we administered intravenously cisplatin (80 mg/mq, day 1), dacarbazine (250 mg/mq/day, days 1-3), vinblastine (2 mg maximum, day 1) every 21 days as first line treatment for patients with unresectable metastases of uveal melanoma and BRAF wild type.”
> “Partial responses were observed in five (20%) patients, stable disease in 12 (48%) patients; disease control rate was 68%.”
> “Median OS of all the patients was 13 months, median progression free survival was 5.5 months.”
> “Five (20%) patients experienced grade 3-4 toxicity.”

Source: [Schinzari et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/29076951/)

<a id="topic-2.2.2.1.4-10"></a>

### Chemotherapy in the control group of a randomized trial of isolated hepatic perfusion

> “In the control group, 49% received chemotherapy, 39% immune checkpoint inhibitors, and 9% locoregional treatment other than IHP.”
> “These disappointing outcomes reflect generally poor responses to systemic chemotherapy, which shows minimal efficacy and delivers no detectable survival benefit.”

Source: [Olofsson Bagge et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10414734/)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
